Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Patent
1995-06-07
2000-09-26
Ungar, Susan
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
4241381, 4241411, 4241431, 4241521, 4241551, 4241721, 4241741, 5303871, 5303877, 5303881, 5303882, 53038822, 5303888, 53038885, A61K 39395, C07K 1600
Patent
active
061239399
ABSTRACT:
This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents, which can be used to treat a mammalian host, usually a human, suspected of having cancer or tumor cells by administering the combination in a therapeutically- or synergistically-effective amount. The drug combinations cytotoxic to tumor cells comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and induces an increase in the phosphorylation of c-erbB-2 protein when placed in contact with the tumor cells. Alternatively, the drug combination cytotoxic to tumor cells may comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and causes down modulation or internalization of c-erbB-2 protein. The anti-neoplastic drug is preferably an alkylating agent, most preferably cisplatin. This combination is particularly effective for inhibiting the growth of breast and ovarian tumor cells. Methods for killing target tumor cells are contemplated by contacting the target cells with the novel drug combinations, methods for treating mammals by administering therapeutic amounts of the drug combinations are also contemplated.
REFERENCES:
patent: 4093607 (1978-06-01), Sela et al.
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 4699877 (1987-10-01), Cline et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 6836414 (1986-03-01), King et al.
patent: 7389920 (1989-08-01), Stuart et al.
Harris et al (Tibtech, 11:42-44, 1993).
Aboud-Pirak et al., JNCI, vol. 80 (20), p. 1605, Dec. 2, 1988.
Oncogene 2, Drebin et al., pp. 273-277.
"Immunotherapy and Monoclonal Ab.", Genes & Cancer, Wiley & Sons, pp. 183-187, 1990.
"Identification of a Phosphoprotein . . . ", Skashmi Charan Padhy et al., Cell, vol. 20, Apr. 1982, pp. 865-871.
"Monoclonal antibodies identify a cell-surface . . . ", Jeffrey A. Drebin et al., Nature, vol. 312, Dec. 6, 1984, pp. 545-548.
"The neu oncogene: an erb-B-related gene . . . ", Alan L. Schecter et al., Nature, vol. 312, Dec. 6, 1994, pp. 513-516.
"The Product of the Human c-erbB-2 Gene: . . . ", Tetsu Akiyama et al., Science, vol. 232, 1986, pp. 1644-1646.
"Expression of the c-erbB-2 Protein . . . ", William J. Gullick et al., Int. J. Cancer, vol. 40, 1987, pp. 246-254.
Abstract JP 2150293-A2.
Cancer Res., Read et al., vol. 50(13), 1990, 39, 47-51 (Abstract).
"The Development of Biological Therapies for Breast Cancer", Marc E. Lippman, Science, vol. 259, Jan. 29, 1993, pp. 631-632.
"Genentech Inc. Cancer Drug Shows Promise", Wall Street Journal, vol. 126(101), May 1992.
"p185.sup.HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro . . . ", R. Hudziak et al., Mol. Cell. Biol., vol. 9, 1989, pp. 1165-1172.
"Alkylating Agents and Immunotoxins Exert Synergistic Antitumor . . . ", Y. Lidor et al., Proceedings of the Amer. Assoc. for Cancer Research, vol. 30(401), 1989.
"A Synergistic Effects Between Anti-Idiotype Antibodies and . . . ", E. Hurwitz et al., Oncogene, vol. 2, 1988, pp. 387-394.
"Monoclonal antibodies specific for the neu oncogene product . . . ", Drebin et al., Oncogene, vol. 2, 1988, pp. 387-394.
"The development and characterization of antibodies to different . . . ", Langton et al., Amer. Assoc. for Cancer Research Conf., May 24-27, 1989.
"Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian . . . ", Science, vol. 244, 1989, pp. 707-712.
"Human Breast Cancer: Correlation of Relapse and Survival with . . . ", Slamon et al., Science, vol. 235, 1987, pp. 177-182.
"Experimental approaches to hypothetical protooncogene", Yarden et al., Proc. Natl. Acad. Sci. USA, vol. 86, 1989, pp. 3179-3183.
U.S. application No. 06/836,414, King et al., filed Mar. 05, 1986.
U.S. application No. 07/389,920, Stuart et al., filed Aug. 4, 1989.
"Amplification of a Novel v-erbB-Related Gene in a Human Mammary . . . ", C.R. King et al., Science, vol. 229, 1985, pp. 974-976.*
"The neu Gene: An erbB-Homologous Gene Distinct from and Unlinked to . . . ", A.L. Schechter et al., Science, vol. 229, 1985, pp. 976-978.*
"A v-erbB-related protooncogene, c-erbB-2, is distinct from the cerbB . . . ", K. Semba et al., Proc. Natl. Acad. Sci. USA, vol. 82, 1985, pp. 6497-6501*.
"Tyrosine Kinase Receptor with Extensive Homology to EFG Receptor . . . ", L. Coussens et al., Science, vol. 230, 1985, pp. 1132-1139.*
"Down-Modulation of an Oncogene Protein Product and Reversion of the . . . ", J.A. Drebin et al., Cell, vol. 41, 1985, pp. 695-706.*
"Direct Interaction of a Ligand for the erbB2 Oncogene Product with . . . ", R. Lupu et al., Science, vol. 249, 1990, pp. 1552-1555.*
"Overepression of the EGF receptor-related proto-oncogene erbB-2 in . . . ", M.H. Kraus et al., The EMBO Journal, vol. 6, 1987, pp. 605-610.*
"The epidermal growth factor receptor and the product of the neu . . . ", Connelly et al., Proc. Natl. Acad. Sci. USA, vol. 87, 1990, pp. 6054-6057*.
"Amplified expression of the HER2/ERBB2 oncogene induces resistance . . . ", Hudziak et al., Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 5102-5106.*
"Identification of a Ligand for the c-kit Proto-Oncogene", Williams et al., Cell, vol. 63, 1990, pp. 167-174.*
"Candidate ligand for the c-kit transmembrane kinase receptor: . . . ", Nocka et al., The EMBO Journal, vol. 9, 1990, pp. 3287-3294.*
"Human proto-oncogene c-kit: a new cell surface receptor tyrosine . . . ", Y. Yarden et al., The EMBO Journal, vol. 6, 1987, pp. 3341-3351.*
"Biochemical basis for cisplatin and 5-fluorouracil synergism in . . . ", Scanlon et al., Proc. Natl. Acad. Sci. USA, vol. 83, 1986, pp. 8923-8925.*
"Molecular Basis of Cisplatin Resistance in Human Carcinomas: Model . . . ", Scanlon et al., Anticancer Research, vol. 9, 1989, pp. 1301-1312.*
"Effect of Cisplatin on the Plasma Membrane . . . ", Aggarwal et al., J. of Histochemistry & Cytochemistry, vol. 31, 1985, pp. 307-317.*
"Dissociation of cellular responses to epidermal growth factor . . . ", Defize et al., The EMBO Journal, vol. 5, 1986, pp. 1187-1192.*
"The Role of Antireceptor Antibodies in Stimulating Phosphorylation . . . ", Zick et al., J. of Biol. Chemis., vol. 259, 1984, pp. 4396-4400.*
"Agonistic antibodies stimulate the kinase encodes by the neu . . . ", J. Yarden, Proc. Natl. Acad. Sci.USA, vol. 87, 1990, pp. 2569-2573.*
Brandis John W.
Hancock Miriam E. C.
Mann Elaina
Mischak Ronald P.
Monahan John J.
Berlex Laboratories Inc.
Ungar Susan
LandOfFree
Anti-neoplastic drugs in cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-neoplastic drugs in cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-neoplastic drugs in cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2097507